Portal de Periódicos da CAPES

Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists

2005; Elsevier BV; Volume: 118; Issue: 5 Linguagem: Inglês

10.1016/j.amjmed.2005.01.028

1555-7162

Antonio Fernández‐Nebro, Eva Tomero, Vera Ortiz-Santamaría, María Carmen Castro, Alejandro Olivé, M. de Haro, Rosa García-Vicuña, María Victoria González-Mari, A Laffón, Rosario García‐Vicuña,

Systemic Lupus Erythematosus Research

Secondary amyloidosis occurs in 5% of patients with poorly controlled, slow-developing chronic inflammatory diseases, mainly rheumatoid arthritis or spondyloarthropathies. 1 Hawkins P.N. Diagnosis and treatment of amyloidosis. Ann Rheum Dis. 1997; 56: 631-633 Crossref PubMed Scopus (19) Google Scholar Unless the activity of the underlying disease can be effectively controlled, the development of secondary amyloidosis is associated with a poor prognosis and reduces the survival rate of these patients. 2 Myllykangas-Luosujarvi R. Aho K. Kautiainen H. Hakala M. Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland. Rheumatology (Oxford). 1999; 38: 499-503 Crossref PubMed Scopus (47) Google Scholar Until now, therapeutic approaches have yielded poor results, with the exception of alkylating agents. However, the high toxicity of these drugs often complicates patient management. Tumor necrosis factor-alpha antagonists are changing the clinical course of some inflammatory diseases, but experience in patients with secondary amyloidosis is scarce. 3 Verschueren P. Lensen F. Lerut E. et al. Benefit of anti-TNF alpha treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis (letter). Ann Rheum Dis. 2003; 62: 368-369 Crossref PubMed Scopus (38) Google Scholar , 4 Elkayam O. Hawkins P.N. Lachmann H. Yaron M. Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum. 2002; 46: 2571-2573 Crossref PubMed Scopus (101) Google Scholar , 5 Drewe E. McDermott E.M. Powell R.J. Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome (letter). N Engl J Med. 2000; 343: 1044-1045 Crossref PubMed Scopus (108) Google Scholar , 6 Gottenberg J.E. Merle-Vincent F. Bentaberry F. et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides a followup report of tolerability and efficacy. Arthritis Rheum. 2003; 48: 2019-2024 Crossref PubMed Scopus (188) Google Scholar , 7 Serratrice J. Granel B. Disdier P. Weiller P.J. Dussol B. Resolution with etanercept of nephrotic syndrome due to renal AA amyloidosis in adult Still’s disease (letter). Am J Med. 2003; 115: 589-590 Abstract Full Text Full Text PDF PubMed Scopus (31) Google Scholar , 8 Ciboddo G. Idone C. Treatment of renal amyloidosis in rheumatoid arthritis requires further investigation comment on the case report by Elkayam et al. Arthritis Rheum. 2003; 48 (author reply 3299–3300): 3299 Crossref PubMed Scopus (2) Google Scholar The aim of our study was to assess the efficacy and safety of anti-tumor necrosis factor agents in a series of 25 Spanish patients with amyloidosis secondary to a rheumatic disease. ErrataThe American Journal of MedicineVol. 119Issue 2PreviewSeshadri P, Iqbal N, Stern L, Williams M, Chicano KL, Daily DA, McGrory J, Gracely EJ, Rader DJ, Samaha FF. A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am J Med. 2004;117:298-405. Full-Text PDF